The overexpression of PLK1 is a hallmark of many types of human cancers, including melanoma, ovarian carcinoma, breast, prostate, thyroid cancers, and glioma [63,64,65], and it is associated with chemoresistance and poor patient outcomes. Here, PLK1 is linked to cancer.